European stocks closed higher on Thursday as an interest rate cut by the Bank of England (BoE), and some encouraging earnings updates and economic data helped ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

After holding firm till around mid afternoon on Wednesday, European stocks pared gains and closed weak as investors assessed the ...

Fintel reports that on October 30, 2024, EF Hutton initiated coverage of Carisma Therapeutics (NasdaqGM:CARM) with a Buy ...

Global Alcoholic Hepatitis Treatment MarketAccording to a recent analysis by Future Market Insights (FMI), the global ...

Madrigal Pharmaceuticals (NASDAQ ... However, the bigger story for me was the revenue generation, which was reported to be $14.6M in net sales of Rezdiffra. In addition, the company reported ...

She sits on the Boards of Hikma Pharmaceuticals, Sensei Therapeutics and Canary Medical.